Introduction: Cognitive dysfunction is prevalent in depressive as well as manic episodes in individuals with Bipolar Disorder (BD). Even more, after symptom remission, many individuals with BD experience persisting cognitive impairment also in euthymic periods, leading to high illness burden and low quality of life. According to a recent research in animals and healthy humans, microbiota may influence cognitive processes via the brain-gut axis. A strategy to examine the role of the microbiota in different diseases is the intake of supplements that modulate the gut microbiome. The aim of this pilot study was to analyze the impact of probiotic supplements on cognitive parameters in a cohort of euthymic individuals with BD, receiving daily probiotic treatment over a time period of 3 months. Methods: A total of 20 euthymic individuals with BD received probiotic supplement over a time period of 3 months and completed a cognitive test battery at 3 time points (t1 at time of inclusion, t2 after one month and t3 after 3 months of probiotic intake). Results: We found a significant improvement of performance concerning attention and psychomotor processing speed measured with the Digit Symbol Test after one (t2) as well as after 3 months (t3) of treatment (F = 8.60; η2 = 0.49, p < 0.01). Furthermore, executive function measured with the TMT-B, increased significantly over 3 months (F = 3.68; η2 = 0.29, p < 0.05). Conclusion: The results confirm the hypotheses that probiotic supplement might help stable individuals with BD to improve the cognitive function, which in turn might lead to better psychosocial, occupational, work and financial functioning. Nevertheless, the idea of this potential new treatment is challenging because of the variety of the human’s gut microbiota.

1.
Lackner N, Bengesser SA, Birner A, Painold A, Fellendorf FT, Platzer M, Reininghaus B, Weiss EM, Mangge H, McIntyre RS, Fuchs D, Kapfhammer HP, Wallner-Liebmann SJ, Reininghaus EZ: Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. World J Biol Psychiatry 2016; 17: 535–546.
2.
Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P: Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114–125.
3.
Thompson JM, Gallagher P, Hughes JH, Watson S, Gray JM, Ferrier IN, Young AH: Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005; 186: 32–40.
4.
Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, Benabarre A, Goikolea JM, Brugue E, Daban C, Salamero M: Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004; 6: 224–232.
5.
Zarate CA,Jr, Tohen M, Land M, Cavanagh S: Functional impairment and cognition in bipolar disorder. Psychiatr Q 2000; 71: 309–329.
6.
SayuriYamagata A, Brietzke E, Rosenblat JD, Kakar R, McIntyre RS: Medical comorbidity in bipolar disorder: the link with metabolic-inflammatory systems. J Affect Disord 2017; 211: 99–106.
7.
Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J: Mood and gut feelings. Brain Behav Immun 2010; 24: 9–16.
8.
Cryan JF, Dinan TG: Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–712.
9.
Salagre E, Vieta E, Grande I: The visceral brain: bipolar disorder and microbiota. Rev Psiquiatr Salud Ment 2017; 10: 67–69.
10.
Sturgeon C, Fasano A: Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016; 4:e1251384.
11.
Hoban AE, Stilling RM, Moloney G, Shanahan F, Dinan TG, Clarke G, Cryan JF: The microbiome regulates amygdala-dependent fear recall. Mol Psychiatry 2018; 23: 1134–1144.
12.
Lowry CA, Smith DG, Siebler PH, Schmidt D, Stamper CE, Hassell JE Jr, Yamashita PS, Fox JH, Reber SO, Brenner LA, Hoisington AJ, Postolache TT, Kinney KA, Marciani D, Hernandez M, Hemmings SM, Malan-Muller S, Wright KP, Knight R, Raison CL, Rook GA: The microbiota, immunoregulation, and mental health: implications for public health. Curr Environ Health Rep 2016; 3: 270–286.
13.
Alam R, Abdolmaleky HM, Zhou JR: Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet 2017; 174: 651–660.
14.
Ait-Belgnaoui A, Colom A, Braniste V, Ramalho L, Marrot A, Cartier C, Houdeau E, Theodorou V, Tompkins T: Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterol Motil 2014; 26: 510–520.
15.
Wallace CJK, Milev R: The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16: 14.
16.
Frohlich EE, Farzi A, Mayerhofer R, Reichmann F, Jacan A, Wagner B, Zinser E, Bordag N, Magnes C, Frohlich E, Kashofer K, Gorkiewicz G, Holzer P: Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun 2016; 56: 140–155.
17.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506–514.
18.
Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, Macqueen G, Sherman PM: Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011; 60: 307–317.
19.
Savignac HM, Tramullas M, Kiely B, Dinan TG, Cryan JF: Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res 2015; 287: 59–72.
20.
Tang F, Reddy BL, Saier MH Jr: Psychobiotics and their involvement in mental health. J Mol Microbiol Biotechnol 2014; 24: 211–214.
21.
Zhou L, Foster JA: Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr Dis Treat 2015; 11: 715–723.
22.
Nguyen TT, Kosciolek T, Eyler LT, Knight R, Jeste DV: Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. J Psychiatr Res 2018; 99: 50–61.
23.
Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, Young VB, Ellingrod VE, McInnis MG: The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res 2017; 87: 23–29.
24.
Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL: Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 2017; 37: 261–267.
25.
Painold AM, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser SA, Birner A, Fellendorf FT, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G, Reininghaus EZ: A step ahead: exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord 2018, Epub ahead of print.
26.
Reininghaus EZ, Wetzlmair LC, Fellendorf FT, Platzer M, Queissner R, Birner A, Pilz R, Hamm C, Maget A, Rieger A, Prettenhofer A, Wurm W, Mörkl S, Dalkner N: Probiotic treatment in individuals with euthymic bipolar disorder – a pilot-study on clinical changes and compliance. Neuropsychobiology 2018, in press.
27.
Wittchen HU, Zaudig M, Fydrich T: Structured Clinical Interview for DSM-IV Axis I and II–SCID. Göttingen, 1992, Hogrefe.
28.
Hamilton M: Hamilton depression scale, ECDEU assessment manual for psychopharmacology. Revised Edition Rockville 1978; 179–192.
29.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435.
30.
Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G: Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14: 491–502.
31.
Kammer DA: A study of the psychometric properties of the German Beck Depression Inventory (BDI). Diagnostica 1993; 29: 48–60.
32.
Krüger S, Bräunig P, Shugar G: Manie-Selbstbeurteilungsskala. Deutsche Bearbeitung des Self-Report Manic Inventory (SRMI). Göttingen, 1997, Beltz Test GmbH.
33.
Reitan RM: Trail Making Test: Manual for Administration and Scoring. Reitan Neuropsychology Laboratory, 1992.
34.
Petermann F, Lepach AC: Wechsler Memory Scale – Fourth Edition, German Edition, Frankfurt, 2012.
35.
Schulter G, Mittenecker E, Papousek I: A computer program for testing and analysing random generation behavior in normal and clinical samples: The Mittenecker Pointing Test (MPT). Behav Res Methods 2010; 42: 333–341.
36.
Mayer EA, Tillisch K, Gupta A: Gut/brain axis and the microbiota. J Clin Invest 2015; 125: 926–938.
37.
Foster JA, McVey Neufeld KA: Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305–312.
38.
Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG: The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008; 43: 164–174.
39.
Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG: Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010; 170: 1179–1188.
40.
Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, Houdeau E, Fioramonti J, Bueno L, Theodorou V: Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 2012; 37: 1885–1895.
41.
McCusker RH, Kelley KW: Immune-neural connections: how the immune system’s response to infectious agents influences behavior. J Exp Biol 2013; 216: 84–98.
42.
Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H: Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005; 19: 453–460.
43.
Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S: Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011; 108: 3047–3052.
44.
Wang H, Lee IS, Braun C, Enck P: Effect of probiotics on central nervous system functions in animals and humans: a systematic review. J Neurogastroenterol Motil 2016; 22: 589–605.
45.
Davari S, Talaei SA, Alaei H, Salami M: Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome-gut-brain axis. Neuroscience 2013; 240: 287–296.
46.
Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM: Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011; 105: 755–764.
47.
Chung YC, Jin HM, Cui Y, Kim DS, Jung JM, Park JI, Jung ES, Choi EK: Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults. J Funct Foods 2014; 10: 465–474.
48.
Benton D, Williams C, Brown A: Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 2007; 61: 355–361.
49.
Bagga D, Reichert JL, Koschutnig K, Aigner CS, Holzer P, Koskinen K, Eichinger CM, Schopf V: Probiotics drive gut microbiome triggering emotional brain signatures. Gut Microbes 2018; 3: 1–11.
50.
Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA: Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394–1401.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.